MDPI Contact

MDPI
St. Alban-Anlage 66,
4052 Basel, Switzerland
Support contact
Tel. +41 61 683 77 34
Fax: +41 61 302 89 18

For more contact information, see here.

秒速赛车开奖直播:Advanced Search

You can use * to search for partial matches.

Search Results

1 article matched your search query. Search Parameters:
Authors = Eliscer Guzman

秒速赛车是哪里的开奖 www.0dv0k.cn Matches by word:

ELISCER (1) , GUZMAN (190)

View options
order results:
result details:
results per page:
Articles per page View Sort by
Displaying article 1-50 on page 1 of 1.
Export citation of selected articles as:
Open AccessReview Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
Received: 29 June 2018 / Revised: 11 July 2018 / Accepted: 11 July 2018 / Published: 13 July 2018
PDF Full-text (566 KB) | HTML Full-text | XML Full-text
Abstract
The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma LDL-cholesterol (LDL-C) levels can be controlled. Initially, the therapeutic
  • 帝豪GL全新智能系统 为了更聪明而升级 2018-12-17
  • 点亮文化自信之灯,塑造大国气质 2018-12-17
  • 中消协启动App个人信息收集测评 测评哪款App你说了算 2018-12-16
  • 军情锐评:搬起石头砸自己脚?特朗普限制中国留学生或削弱美科研能力 2018-12-16
  • 海印公园北片物业及配套停车场出租项目 2018-12-15
  • 宁夏科技馆科普“粽”宴等你来 2018-12-15
  • 淳安县:构建“大调解”体系 2018-12-15
  • 探访玉麦守边人(新时代·面孔) 2018-12-15
  • 用责任制拧紧安全阀(快评) 2018-12-14
  • 世界杯亚洲“常客”给中国足球带来的启示 2018-12-14
  • 保险业偿付能力充足整体风险可控 2018-12-13
  • “东方夜莺”杨学进悉尼举办上海老歌独唱音乐会 2018-12-13
  • 新时代 新气象 新作为 学习宣传贯彻党的十九大精神 2018-12-13
  • 揭秘:中纪委如何对高级领导干部进行谈话提醒? 2018-12-12
  • 陕西国防工业职业技术学院百名大学生志愿者敬老院慰问孤寡老人陕西国防工业职业技术学院百名大学生志愿者敬老院慰问-陕西教育新闻 2018-12-12
  • 863| 79| 511| 621| 683| 578| 303| 23| 947| 368| [...] Read more.
    The discovery of proprotein convertase subtilisin-kexin type 9 (PCSK9), a serine protease which binds to the low-density lipoprotein (LDL) receptors and targets the receptors for lysosomal degradation, offered an additional route through which plasma LDL-cholesterol (LDL-C) levels can be controlled. Initially, the therapeutic approaches to reduce circulating levels of PCSK9 were focused on the use of monoclonal antibodies. To that effect, evolocumab and alirocumab, two human monoclonal antibodies directed against PCSK9, given on a background of statin therapy, have been shown to markedly decrease LDL-C levels and significantly reduce cardiovascular risk. The small interfering RNA (siRNA) molecules have been used recently to target the hepatic production of PCSK9. siRNA interferes with the expression of specific genes with complementary nucleotide sequences by affecting the degradation of mRNA post-transcription, thus preventing translation. Inclisiran is a long-acting, synthetic siRNA directed against PCSK9 and it has been shown to significantly decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels. This review aims to present and discuss the current clinical and scientific evidence pertaining to inclisiran, which is a new promising agent in the management of hypercholesterolemia. Full article
    Figures

    Figure 1

    Figure 1
    <p>Mechanism of action of inclisiran in conjunction with the action of PCSK9.</p>
    Full article ">

    Years

    Subjects

    Refine Subjects

    Journals

    Refine Journals

    Article Types

    Refine Types

    Countries / Territories

    Refine Countries / Territories
    秒速赛车是哪里的开奖
    Back to Top